All In Biotech

Drug Trial Radar · NCT07024641

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Nov 13, 2024

Primary completion

Nov 2028

Study completion Nov 2028

Sponsor

Lead sponsor
GigaGen, Inc.Industry
Sponsor type
Industry
First posted
Jun 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to assess the safety and tolerability of single and multiple intravenous (IV) doses of GIGA-2339 in participants with chronic Hepatitis B Virus (HBV) infection.

Conditions

  • Hepatitis B Virus Infection

Interventions

  • GIGA-2339Drug

    Administered by intravenous infusion

  • PlaceboDrug

    Administered by intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SAD and MAD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: SAD: Up to Day 105; MAD: Up to Day 245

Locations

20 sites in 5 countries. Site status is shown where the registry gives one.

  • Grifols Investigative site

    Chandler, Arizona · Recruiting

  • Grifols Investigative site

    Huntington Beach, California · Recruiting

  • Grifols Investigative site

    Lake Forest, California · Recruiting

  • Grifols Investigative site

    Long Beach, California · Recruiting

  • Grifols Investigative site

    Oakland, California · Suspended

  • Grifols Investigative Site

    Peachtree Corners, Georgia · Recruiting

  • Grifols Investigative Site

    Iowa City, Iowa · Recruiting

  • Grifols Investigative Site

    Lenexa, Kansas · Recruiting

  • Grifols Investigative site

    Baltimore, Maryland · Recruiting

  • Grifols Investigative site

    San Antonio, Texas · Recruiting

  • Grifols Investigative site

    Webster, Texas · Recruiting

  • Grifols Investigative site

    Richmond, Virginia · Recruiting

  • Grifols Investigate Site

    Concord, New South Wales, Australia · Recruiting

  • Grifols Investigative site

    Fortitude Valley, Queensland, Australia · Recruiting

  • Grifols Investigative site

    Hong Kong, Hong Kong Island, Hong Kong · Recruiting

  • Grifols Investigative site

    Shatin, New Territories, Hong Kong · Recruiting

  • Grifols Investigative site

    Seogu, Busan, South Korea · Recruiting

  • Grifols Investigative site

    Songpa-dong, Seoul, South Korea · Recruiting

  • Grifols Investigative site

    Sanmin, Kaohsiung, Taiwan · Recruiting

  • Grifols Investigative site

    Zhongzheng, Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.